Infinity Pharmaceuticals, Inc. (INFIQ)

Market Cap	91.00
Revenue (ttm)	2.57M
Net Income (ttm)	-40.95M
Shares Out	90.76M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,936
Average Volume	1,461
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	-3.61
RSI	40.93
Earnings Date	n/a

About Theseus Pharmaceuticals

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 30
• Stock Exchange: OTCMKTS
• Ticker Symbol: INFIQ

Financial Performance

In 2022, Infinity Pharmaceuticals's revenue was $2.59 million, an increase of 39.56% compared to the previous year's $1.86 million. Losses were -$44.37 million, -1.97% less than in 2021.